Healthcare [ 12/13 ] | Diagnostics & Research [ 56/164 ]
NASDAQ | Common Stock
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally.
The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
It also offers clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization.
In addition, the company provides laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers.
Further, it offers adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions.
The company serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations.
ICON Public Limited Company was incorporated in 1990 and is headquartered in Dublin, Ireland.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Apr 25, 24 | 3.47 Increased by +19.66% | 3.41 Increased by +1.76% |
| Mar 12, 24 | 3.46 Increased by +10.54% | 3.44 Increased by +0.58% |
| Oct 25, 23 | 3.30 Increased by +10.00% | 3.28 Increased by +0.61% |
| Jul 26, 23 | 3.11 Increased by +8.74% | 3.08 Increased by +0.97% |
| Apr 26, 23 | 2.90 Increased by +5.07% | 2.88 Increased by +0.69% |
| Feb 22, 23 | 3.13 Increased by +19.01% | 3.05 Increased by +2.62% |
| Nov 2, 22 | 3.00 Increased by +17.65% | 2.94 Increased by +2.04% |
| Jul 27, 22 | 2.86 Increased by +25.99% | 2.79 Increased by +2.51% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 23 | 2.07 B Increased by +5.31% | 216.42 M Increased by +84.27% | Increased by +10.47% Increased by +74.97% |
| Sep 30, 23 | 2.06 B Increased by +5.80% | 163.66 M Increased by +2.19% | Increased by +7.96% Decreased by -3.41% |
| Jun 30, 23 | 2.02 B Increased by +4.40% | 115.60 M Decreased by -0.12% | Increased by +5.72% Decreased by -4.32% |
| Mar 31, 23 | 1.98 B Increased by +4.04% | 116.65 M Increased by +4.18% | Increased by +5.90% Increased by +0.14% |
| Dec 31, 22 | 1.96 B Increased by +4.08% | 117.44 M Increased by +53.59% | Increased by +5.99% Increased by +47.57% |
| Sep 30, 22 | 1.94 B Increased by +4.08% | 160.15 M Increased by +269.89% | Increased by +8.25% Increased by +263.23% |
| Jun 30, 22 | 1.94 B Increased by +122.14% | 115.73 M Increased by +56.68% | Increased by +5.98% Decreased by -29.47% |
| Mar 31, 22 | 1.90 B Increased by +121.60% | 111.97 M Increased by +15.29% | Increased by +5.89% Decreased by -47.97% |